Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil

DOI: 10.1124/jpet.107.133405
Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 62-8.

#	Paper	IF	Citations
18	Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. *Cellular Signalling*, **2009**, 21, 1768-74	4.9	18
17	Cyclic GMP-hydrolyzing phosphodiesterases. *Handbook of Experimental Pharmacology*, **2009**, 367-408	3.2	28
16	cGMP: Generators, Effectors and Therapeutic Implications. *Handbook of Experimental Pharmacology* , **2009**,	3.2	13
15	Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction. **2010**, 135-172		
14	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. *Pharmacological Reviews*, **2010**, 62, 525-63	22.5	677
13	Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. *Handbook of Experimental Pharmacology*, **2011**, 47-84	3.2	41
12	Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models. *PLoS ONE*, **2011**, 6, e19922	3.7	9
11	Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil. *Cellular Signalling*, **2011**, 23, 778-84	4.9	4
10	Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. *Cellular Signalling*, **2011**, 23, 1578-83	4.9	5
9	Bis-halogen-anthraniloyl-substituted nucleoside 5′-triphosphates as potent and selective inhibitors of Bordetella pertussis adenylyl cyclase toxin. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 336, 104-15	4.7	21
8	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. *Physiological Reviews*, **2011**, 91, 651-90	47.9	443
7	The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s). *Biochemical Journal*, **2014**, 459, 539-50	3.8	20
6	Phosphodiesterases and Cyclic Nucleotide Signaling In The CNS. **2014**, 1-46		2
5	Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects. *Proteins: Structure, Function and Bioinformatics*, **2015**, 83, 25-36	4.2	13
4	Eukaryotic-Type Ser/Thr Protein Kinase Mediated Phosphorylation of Mycobacterial Phosphodiesterase Affects its Localization to the Cell Wall. *Frontiers in Microbiology*, **2016**, 7, 123	5.7	4
3	2-AMINOETHYLDIPHENYLBORINATE MODIFIES THE PULMONARY CIRCULATION IN PULMONARY HYPERTENSIVE NEWBORN LAMBS WITH PARTIAL GESTATION AT HIGH ALTITUDE. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2016**, 311, L788-L799	5.8	10
2	Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. *Biomedicine and Pharmacotherapy*, **2021**, 134, 111128	7.5	15

1	cGK substrates. *Handbook of Experimental Pharmacology*, **2009**, 163-93	3.2	38